1-10 of 10
William J. Kell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Effectiveness of Asciminib in Patients with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: A Global Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

Dragana Milojkovic, Nicole Blijlevens, Yok-Lam Kwong, Uzma Zaidi, Fausto Castagnetti, Paolo Gallipoli, Maria Cristina Miggiano, Peter E Westerweel, Melissa Chen, M. Carmen Garcia Hernandez, William J. Kell, Pankit Vachhani, Neha Agarwal, Alessandra Colasante, Sridhar Meka, Aoife Smyth, Germano Ferreira, Jeroen J.W.M. Janssen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4541.
https://doi.org/10.1182/blood-2023-181937
Published: 2023
Journal Articles

HM-PRO: A Novel Patient-Reported Outcome Measure in Hematological Malignancy for Use in Clinical Practice

Pushpendra Goswami, PhD MSc, BPharm, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP, Tatyana Ionova, PhD, Esther Natalie Oliva, MD, Adele K Fielding, MBBS,PhDFRCP,FRCPath, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham Collins, MD PhD, Stewart McConnell, Catherine Langton, Daniel Jennings, Roger Else, William J. Kell, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2176.
https://doi.org/10.1182/blood.V130.Suppl_1.2176.2176
Published: 2017
Journal Articles

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

Alan K Burnett, MD, Robert K Hills, MA, MSc, DPhil, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, John L Yin, MD, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Lars Kjeldsen, MD, PhD, David Bowen, Nigel H. Russell, MD
Journal: Blood
Blood (2011) 118 (21): 582.
https://doi.org/10.1182/blood.V118.21.582.582
Published: 2011
Journal Articles

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

Alan Burnett, Robert Hills, MA, MSc, DPhil, Ann Elizabeth Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, FRCP, FRCPath, William J. Kell, MD, MB, Keith Wheatley, John Yin, MD, Mary Frances McMullin, MD, Helen Dignum, David Bowen, Nigel H. Russell, MD
Journal: Blood
Blood (2010) 116 (21): 18.
https://doi.org/10.1182/blood.V116.21.18.18
Published: 2010
Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Arsenic Trioxide: the UK NCRI AML16 “Pick a Winner” Comparison.

Nigel H. Russell, MD, Robert K Hills, Ann E. Hunter, MBBS, FRCP, FRCPath, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Mary Frances McMullin, John AL Yin, David T. Bowen, MD, A. Burnett, MD, FRCP
Journal: Blood
Blood (2009) 114 (22): 486.
https://doi.org/10.1182/blood.V114.22.486.486
Published: 2009
Journal Articles

Low Dose Ara-C Versus Low Dose Ara-C and Tipifarnib: Result of the UK NCRI AML16 “Pick a Winner” Comparison

Alan K. Burnett, MD, FRCP, Robert Hills, MA, MSc, DPhil, Donald Milligan, MD, MBChB, William J. Kell, MD, MB, Keith Wheatley, DPhil, Andres E. Virchis, FRCP, FRCPath, Nigel H. Russell, MD
Journal: Blood
Blood (2008) 112 (11): 2962.
https://doi.org/10.1182/blood.V112.11.2962.2962
Published: 2008
Journal Articles

Treatment of AML in the Elderly: Who Is “Fit” for Intensive Chemotherapy?.

Robert K. Hills, MA, MSc, DPhil, William J. Kell, RCPath,MRCPI, MA, MB, Alan K. Burnett, MD, FRCPath, FRCP
Journal: Blood
Blood (2006) 108 (11): 1974.
https://doi.org/10.1182/blood.V108.11.1974.1974
Published: 2006
Journal Articles

The Feasibility of Combining Daunorubicin, Clofarabine and Gemtuzumab Ozogamicin Is Feasible and Effective. A Pilot Study.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, RCPath,MRCPI, MA, MB, Robert K. Hills, MA,MSc, DPhil, Nigel H. Russell, MD,FRCP,FRCPath, John Yin, MRCP, MRCPath, Ann Hunter, Dominic Culligan
Journal: Blood
Blood (2006) 108 (11): 1950.
https://doi.org/10.1182/blood.V108.11.1950.1950
Published: 2006
Journal Articles

The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial.

Alan K. Burnett, MD, FRCPath, FRCP, William J. Kell, MD, Anthony H. Goldstone, DM, Donald Milligan, FRCP, Ann Hunter, FRCP, Archie G. Prentice, FRCP, Nigel H. Russell, MD, Brenda Gibson, FRCP, Keith Wheatley, DPhil, Robert K. Hills, MA, MSc, DPhil
Journal: Blood
Blood (2006) 108 (11): 13.
https://doi.org/10.1182/blood.V108.11.13.13
Published: 2006
Journal Articles

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

Clinical Trials & Observations
William J. Kell, Alan K. Burnett, Raj Chopra, John A. L. Yin, Richard E. Clark, Ama Rohatiner, Dominic Culligan, Ann Hunter, Archie G. Prentice, Donald W. Milligan
Journal: Blood
Blood (2003) 102 (13): 4277–4283.
https://doi.org/10.1182/blood-2003-05-1620
Published: 2003